These beneficial effects on the clinical course of T1D occurred as a consequence of suppression of inflammation, mediated by AHR-driven upregulation of tolDC and Treg compartments that exerted an immunosuppressive function in the GALT and pancreas. The gene discussed is AHR; the disease is type 1 diabetes mellitus.